Castle Biosciences, Inc. (CSTL) Bundle
A Brief History of Castle Biosciences, Inc. (CSTL)
Foundation and Early Years
Castle Biosciences, Inc. was founded in 2007. The company is headquartered in Friendswood, Texas and focuses on developing and commercializing diagnostic and prognostic tests for skin cancer and other cancers.
Initial Public Offering (IPO)
Castle Biosciences launched its IPO on November 12, 2020, offering 4.25 million shares priced at $16.00 per share, raising approximately $68 million.
Financial Performance
For the fiscal year ending December 31, 2022, Castle Biosciences reported:
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $106.5 million | $72.0 million |
| Net Income (Loss) | ($2.4 million) | ($18.0 million) |
| Total Assets | $135.8 million | $121.4 million |
| Total Liabilities | $45.6 million | $61.2 million |
Product Development
Castle is known for its flagship product, the DecisionDx®-Melanoma, launched in 2017. This test helps assess the risk of metastasis in melanoma patients.
The company also introduced:
- DecisionDx®-Melanoma
- DecisionDx®-SCC
- DecisionDx®-UM
Market Expansion
As of 2023, Castle Biosciences has expanded its market reach, with over 400 institutions utilizing its tests. The company has also secured several collaborations with leading healthcare institutions.
Stock Performance
As of October 2023, the stock price of Castle Biosciences (CSTL) was approximately $14.50, with a market capitalization around $500 million.
Research and Development Investments
In 2022, the company spent approximately $18 million on research and development, which represented about 17% of total revenue.
Corporate Achievements
Castle Biosciences has received numerous awards, including:
- 2021 - Recognized as one of the Best Places to Work by the Houston Chronicle
- 2022 - Included in the Forbes America’s Best Startup Employers list
Future Outlook
Castle Biosciences projects continued growth in the coming years, targeting revenues of approximately $150 million by end of 2024, primarily driven by the increasing demand for its diagnostic solutions.
A Who Owns Castle Biosciences, Inc. (CSTL)
Shareholder Composition
As of the latest filings, Castle Biosciences, Inc. (CSTL) has a diverse group of shareholders ranging from institutional investors to individual shareholders. The following table outlines the major shareholders and their respective ownership percentages.
| Shareholder Type | Name | Ownership Percentage |
|---|---|---|
| Institutional Investor | BlackRock, Inc. | 9.7% |
| Institutional Investor | The Vanguard Group | 8.4% |
| Institutional Investor | State Street Corporation | 5.6% |
| Insider | David J. Miller (CEO) | 2.1% |
| Insider | Brian L. Hargrove (CFO) | 1.8% |
| Institutional Investor | JPMorgan Chase & Co. | 6.2% |
| Other | Retail Investors | 66.2% |
Market Capitalization
As of the latest market close on October 27, 2023, Castle Biosciences, Inc. had a market capitalization of approximately $370 million.
Stock Performance
The stock price of CSTL has shown various fluctuations over the past year. The following table summarizes the key stock performance indicators.
| Metric | Value |
|---|---|
| 52-Week High | $20.15 |
| 52-Week Low | $8.12 |
| Current Stock Price | $12.75 |
| Year-to-Date Return | -15.3% |
| Beta | 1.45 |
Financial Overview
Castle Biosciences, Inc. has reported significant revenue growth in recent quarters. The following table illustrates the company's financial performance metrics for the most recent fiscal year ending June 30, 2023.
| Financial Metric | Value |
|---|---|
| Total Revenue | $100.2 million |
| Net Income | -$25.3 million |
| Operating Expenses | $80.4 million |
| Cash and Cash Equivalents | $50 million |
| Debt | $10 million |
Recent Developments
In the latest earnings call, the management of Castle Biosciences provided insights into their upcoming product launches and market expansion strategies. The following points highlight key developments:
- Introduction of new tests aimed at melanoma and non-melanoma skin cancers.
- Expansion of sales team to increase market penetration.
- Collaborations with major oncology practices for clinical trial participation.
Ownership Changes
Recent SEC filings indicate notable changes in ownership among institutional shareholders, with a few major funds increasing their positions:
- BlackRock increased its stake by +1.5%.
- Vanguard reduced its position by -0.3%.
- State Street increased its holdings by +0.8%.
Conclusion on Ownership Structure
Castle Biosciences, Inc. showcases a mixture of institutional and retail investor ownership, with significant stakes held by prominent investment firms, shaping its strategic direction and market performance.
Castle Biosciences, Inc. (CSTL) Mission Statement
Core Purpose
Castle Biosciences, Inc. is dedicated to improving the lives of patients by providing innovative diagnostic and prognostic tests that enable personalized treatment decisions, particularly in the field of dermatology. The company seeks to empower healthcare providers and patients with actionable insights derived from advanced molecular diagnostics.
Strategic Goals
- To expand the portfolio of proprietary tests to address unmet clinical needs.
- To enhance patient access to personalized medicine through robust reimbursement strategies.
- To achieve sustainable revenue growth while maintaining a focus on research and development.
Recent Financial Performance
As of Q3 2023, Castle Biosciences reported the following financial metrics:
| Financial Metric | Q3 2023 Amount | Q3 2022 Amount | Year-over-Year Growth |
|---|---|---|---|
| Revenue | $34.5 million | $27.1 million | 27% increase |
| Gross Profit | $29.3 million | $21.4 million | 37% increase |
| Net Income | $4.2 million | $1.5 million | 180% increase |
| Operating Expenses | $25.1 million | $20.0 million | 25.5% increase |
Key Products
Castle Biosciences focuses on a range of tests, including:
- DecisionDx®-Melanoma: A test that aids in the management of melanoma patients.
- DecisionDx®-UM: A test designed for uveal melanoma.
- DecisionDx®-SCC: A test for cutaneous squamous cell carcinoma.
Market Position and Reach
As of 2023, Castle Biosciences has positioned itself as a leader in the dermatological diagnostics market, with a projected market share of approximately 30% in the melanoma diagnostic space. The company has expanded its testing services to over 1,200 healthcare institutions nationwide.
Research and Development Focus
Castle Biosciences allocates a significant portion of its budget to research and development, with approximately $10 million earmarked for R&D in 2023. The company aims to introduce at least two new tests by the end of 2024.
Corporate Responsibility
Castle Biosciences is committed to ethical practices and sustainability. In 2023, the company implemented various initiatives aimed at reducing its environmental footprint, including:
- Recycling programs that reduced waste by 15%.
- Energy-efficient laboratory practices leading to a 10% reduction in energy consumption.
Future Vision
The mission of Castle Biosciences extends beyond immediate financial goals. The company envisions a future where:
- All patients have access to advanced diagnostics that inform treatment pathways.
- Healthcare providers are equipped with tools that enhance decision-making.
- Innovative research continues to drive improvements in patient outcomes.
How Castle Biosciences, Inc. (CSTL) Works
Company Overview
Castle Biosciences, Inc. is a commercial-stage diagnostics company that focuses on providing innovative genomic tests to improve the management of cancer patients. Its flagship products include the DecisionDx® portfolio, which includes DecisionDx-Melanoma and DecisionDx-UM.
Business Model
The company employs a laboratory services model, offering tests that analyze the genetic makeup of tumors. These tests support oncologists in determining the likelihood of cancer recurrence and guiding treatment decisions.
Market Focus
Castle Biosciences primarily targets the melanoma and uveal melanoma markets. According to a 2021 market report, the global melanoma therapeutics market was valued at approximately $5.3 billion and is expected to grow at a CAGR of 10.4% from 2021 to 2028.
Financial Performance
As of Q2 2023, Castle Biosciences reported total revenue of $31.8 million, a 19% increase compared to the same period in 2022. The gross profit margin was approximately 81%.
| Financial Metric | Q2 2023 | Q2 2022 | Change (%) |
|---|---|---|---|
| Total Revenue | $31.8 million | $26.7 million | 19% |
| Gross Profit Margin | 81% | 80% | 1% |
| Net Loss | -$8.1 million | -$7.3 million | 11% |
| Cash and Cash Equivalents | $141.2 million | $118.5 million | 19% |
Product Offerings
- DecisionDx-Melanoma
- DecisionDx-UM
- My Skin Cancer App
- Other emerging tests under development
Research and Development
In 2022, Castle Biosciences invested approximately $15.2 million in R&D, focusing on expanding its test offerings and improving existing products.
Regulatory Status
Castle Biosciences’ tests have received CLIA certification, and the company has applied for Medicare reimbursement, which is crucial for commercial success.
Partnerships and Collaborations
Castle has established collaborations with various organizations to advance research and expand its market reach. In 2023, the company signed a strategic partnership with a leading cancer research institute to enhance its clinical data and product efficacy.
Stock Performance
As of October 2023, Castle Biosciences' stock (CSTL) was trading at approximately $34.50, representing a 5.6% increase year-to-date. The market capitalization stood at around $1.1 billion.
Market Challenges
The diagnostic market faces challenges such as regulatory changes, competition from other biotech firms, and the need for continuous innovation to maintain market share.
Future Outlook
Castle Biosciences aims to expand its portfolio with new tests in the oncology space and enhance its market presence, projecting revenue growth of approximately 25% in 2024.
How Castle Biosciences, Inc. (CSTL) Makes Money
Revenue Streams
Castle Biosciences generates revenue primarily through its diagnostic tests, which are focused on aiding in the treatment of skin cancer and other malignancies. In 2022, the total revenue reported by Castle Biosciences was approximately $97.4 million.
Diagnostic Test Offerings
The company offers several key diagnostic products that contribute to its revenue stream:
- DecisionDx-Melanoma
- DecisionDx-UM
- DecisionDx-SCC
- DecisionDx-CRC
Financial Performance
In the most recent fiscal year, Castle Biosciences reported the following financial metrics:
| Metric | 2022 Amount | 2021 Amount |
|---|---|---|
| Total Revenue | $97.4 million | $75.5 million |
| Net Income | -$14.6 million | -$17.8 million |
| Gross Profit | $69.9 million | $54.1 million |
| Operating Expenses | $83.3 million | $67.8 million |
Market Position
Castle Biosciences holds a significant position in the dermatology and oncology markets. The estimated market size for melanoma diagnostics alone is projected to reach $4 billion by 2025, with Castle capturing an expanding share.
Insurance Coverage
A key factor in Castle's revenue generation is the coverage of its tests by major insurance plans. As of 2022, approximately 90% of tests were covered by Medicare and private insurers, enhancing patient accessibility.
Research and Development Investments
Castle continues to invest in R&D to innovate and expand its diagnostic offerings. In 2022, R&D expenses amounted to $27.6 million, reflecting a commitment to future growth.
Sales and Marketing Strategies
The company employs a robust sales force focusing on healthcare providers. In 2022, Castle Biosciences expanded its sales team, resulting in an increase in the adoption rate of its tests, projecting a year-over-year growth of 29%.
Partnerships and Collaborations
Strategic partnerships with key healthcare organizations have bolstered Castle's market presence. Notable collaborations include agreements with prominent hospitals and cancer treatment centers, expanding outreach and enhancing credibility.
Future Projections
Expectations for Castle Biosciences indicate continued revenue growth. Analysts predict a growth rate of approximately 25-30% annually over the next five years, fueled by the increasing prevalence of skin cancer and an expanding product portfolio.
Castle Biosciences, Inc. (CSTL) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support